The Tesla of oral autoimmune disease treatments: developing sleek, new pills to disrupt traditional injectable therapies.

Gilead Sciences for inflammatory diseases, focused on creating breakthrough oral medicines instead of injectables.

A specialized Pfizer for autoimmune pills: developing new oral drugs for inflammatory diseases to offer convenient alternatives.

• VTX-958: An oral S1P1 receptor modulator in clinical development for immune-mediated diseases such as psoriasis, Crohn's disease, and ulcerative colitis.
• VTX-2735: An oral peripheral NLRP3 inflammasome inhibitor being developed to treat a range of inflammatory diseases outside the central nervous system.
• VTX-3232: An oral central nervous system (CNS)-penetrant NLRP3 inflammasome inhibitor designed for the treatment of neuroinflammatory conditions affecting the brain and spinal cord.

Ventyx Biosciences (VTYX) sells primarily to other companies, specifically through collaboration agreements for the discovery, development, and commercialization of small molecule therapeutics.

Its major customer is:

• Janssen Biotech, Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ)

Raju Mohan, PhD, Founder, CEO & Director

Raju Mohan founded Ventyx Biosciences and has served as a member of its board of directors since inception. Prior to Ventyx, he founded Akarna Therapeutics, which was acquired by Allergan for up to $1.2 billion. He also founded Oppilan Pharma, Zomagen Biosciences, Escalier Biosciences, and Vimalan Biosciences, all immunology-focused specialty pharmaceutical companies. Dr. Mohan previously served as Vice President and head of the San Diego site for Exelixis and Vice President of Chemistry at X-Ceptor Therapeutics, which was acquired by Exelixis. He started his pharmaceutical career at Berlex Biosciences, a subsidiary of Bayer/Schering AG, where he held positions of increasing responsibility.

Roy M. Gonzales, CPA, MBA, SVP, Finance, Interim Principal Financial Officer and Interim Principal Accounting Officer

Roy M. Gonzales currently serves as SVP of Finance and assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer effective August 30, 2024. He joined Ventyx Biosciences as Senior Vice President of Finance in April 2024 and was previously Vice President of Accounting from January 2023. His extensive experience in finance includes roles at Landos Biopharma, Histogen, Invesco US, Spinal Elements, Dexcom, and Arena Pharmaceuticals. Mr. Gonzales, a Certified Public Accountant, began his career at KPMG.

John Nuss, PhD, Chief Scientific Officer

John Nuss serves as the Chief Scientific Officer at Ventyx Biosciences. He brings extensive drug development experience to the company.

Matthew Moore, Chief Operating Officer

Matthew Moore serves as the Chief Operating Officer for Ventyx Biosciences.

Mark S. Forman, MD, PhD, Chief Medical Officer

Mark S. Forman serves as the Chief Medical Officer at Ventyx Biosciences. He is a physician scientist with deep expertise in clinical drug development. Prior to joining Ventyx, Dr. Forman served as Chief Medical Officer at Passage Bio, where he oversaw their research and development portfolio focused on gene therapies for central nervous system disease. He has nearly two decades of experience in translational research for neurological disorders, including positions at the Alzheimer's Drug Discovery Foundation, Acadia Pharmaceuticals, and Merck.

The key risks for Ventyx Biosciences (VTYX) primarily revolve around the inherent challenges of drug development, intense market competition, and financial considerations related to funding and cash flow.

1. Clinical Trial and Drug Development Risk: As a clinical-stage biopharmaceutical company, Ventyx Biosciences' success hinges on the positive outcomes of its clinical trials. There is a significant risk that drug candidates, such as VTX3232 and VTX2735, may not demonstrate sufficient efficacy or favorable safety profiles in ongoing or future trials. The potential emergence of safety signals, lower-than-expected efficacy, or failure to meet primary endpoints could lead to delays, termination of development programs, or even abandonment of a drug. An example of this risk materializing was the termination of studies for VTX958 in plaque psoriasis and psoriatic arthritis following disappointing Phase 2 results, which led to a substantial drop in the company's stock price. The design of trials, particularly with multiple secondary endpoints as exploratory, also increases the risk of false positives, which needs to be considered when assessing the probability of success in later-stage trials.
2. Competition: Ventyx Biosciences operates within a highly competitive biopharmaceutical landscape, specifically in the development of oral small molecule therapies for autoimmune, inflammatory, and neurodegenerative diseases. The company faces direct and indirect competition from numerous pharmaceutical and biotechnology companies developing both oral and injectable treatments. The dynamic nature of the pharmaceutical industry, characterized by continuous drug development, mergers, acquisitions, and evolving market trends, means Ventyx's pipeline drugs must demonstrate clear differentiation, superior efficacy, and safety to gain market penetration against existing and emerging therapies.
3. Financial Risk and Funding: Ventyx Biosciences faces financial risks related to its operational funding and the significant capital required to advance its clinical programs. The company has been noted for having a "short cash runway" and a heavy reliance on the success of individual drug candidates. While the probability of bankruptcy has been assessed as relatively low in the immediate term, the progression of its assets to pivotal Phase 3 trials and eventual commercialization will necessitate substantial investment. Any future fundraising efforts, such as equity offerings, could lead to dilution for existing shareholders.

Takeda Pharmaceutical Company's TAK-279, an oral TYK2 inhibitor, presents an emerging competitive threat to Ventyx Biosciences, particularly impacting their lead asset VTX958. TAK-279 is in the same drug class as VTX958 and targets the same major indications, including psoriasis and psoriatic arthritis. Takeda has reported strong Phase 2b clinical trial results for TAK-279 in psoriasis, demonstrating high efficacy rates that are comparable to or potentially even superior to existing or competing TYK2 inhibitors. With TAK-279 advancing to Phase 3 trials, it has a significant lead in development over VTX958, which is still in Phase 2 for multiple indications. If TAK-279 continues to demonstrate a compelling efficacy and safety profile through late-stage development, it could capture a substantial market share and make it challenging for VTX958 to differentiate and secure a strong position upon potential approval, especially given the established presence of Bristol Myers Squibb's deucravacitinib (Sotyktu).

Ventyx Biosciences (VTYX) is developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, with a pipeline that includes NLRP3 inhibitors, S1P1R modulators, and TYK2 inhibitors. The addressable markets for these main product categories are substantial and are primarily global, with North America often leading in market share.

NLRP3 Inhibitors

The global market for NLRP3 Inflammasome Inhibitors was estimated at approximately $1.16 billion in 2024 and is projected to reach around $10.81 billion by 2033, demonstrating a robust Compound Annual Growth Rate (CAGR) of 28.4% from 2025 to 2033. Another estimate places the global market size at $1.12 billion in 2024, growing to $5.43 billion by 2033 with an 18.3% CAGR. North America is a significant region in this market, accounting for approximately 43% of the global market in 2024, equivalent to about $499 million.

S1P Receptor Modulators (including S1P1R modulators)

The global S1P Receptor Modulator Drugs market was valued at over $2.98 billion in 2024 and is anticipated to reach $8.01 billion by 2037, with a CAGR of approximately 7.9% between 2025 and 2037. Other projections indicate the global S1P receptor modulator market could be between $1.1 billion and $2.1 billion in 2025, or $2.89 billion in 2024 growing to $6.86 billion by 2035 with an 8.17% CAGR. Some analyses forecast the market to reach an estimated $12.5 billion by 2025. North America and Europe are noted as leading regions in this market.

TYK2 Inhibitors

The global TYK2 inhibitor market was approximately $1.5 billion in 2025 and is projected to experience a CAGR of 15% from 2025 to 2033. Another source estimates the global TYK2 Inhibitor Market size at $1.95 billion in 2024, expected to grow from $2.15 billion in 2025 to $5.7 billion by 2035, with a CAGR of around 10.2% during that period. North America holds the largest market share for TYK2 inhibitors, with the U.S. market experiencing significant growth due to the high prevalence of autoimmune diseases.

• Successful Advancement and Potential Commercialization of VTX3232 in Obesity and Cardiometabolic Diseases: Ventyx recently reported positive topline results from a Phase 2 study of its CNS-penetrant NLRP3 inhibitor, VTX3232, in participants with obesity and cardiovascular risk factors in October 2025. The study demonstrated significant reductions in inflammatory markers such as hsCRP and IL-6, which could position VTX3232 as a treatment for cardiometabolic benefits. Further development and potential market entry in these indications are crucial for future revenue.
• Successful Advancement and Potential Commercialization of VTX3232 in Parkinson's Disease: Ventyx announced positive topline results from its Phase 2a biomarker trial evaluating VTX3232 in patients with early Parkinson's disease in June 2025. The company is on track to complete this trial in Q2 2025 and is planning for the next phase of development, highlighting the potential for this compound in neurodegenerative diseases.
• Successful Advancement and Potential Commercialization of VTX2735 in Recurrent Pericarditis: VTX2735, a peripherally restricted NLRP3 inhibitor, is undergoing a Phase 2 trial for recurrent pericarditis. Topline results from this study are expected in the fourth quarter of 2025. If successful, this oral therapy could address a rare, debilitating autoinflammatory condition affecting a significant patient population.
• Strategic Expansion of the NLRP3 Inhibitor Portfolio into Additional Indications: Ventyx is establishing itself as a leader in NLRP3 inhibitors. Beyond the current lead indications, VTX3232 has potential therapeutic utility for a range of neuroinflammatory diseases, including Alzheimer's disease and multiple sclerosis, as well as other cardiometabolic conditions. Similarly, VTX2735 may be evaluated for other cardiovascular conditions where NLRP3 activation plays a role. Successful exploration and development in these broader markets could significantly contribute to long-term revenue growth.

Share Issuance

• Ventyx Biosciences completed its Initial Public Offering (IPO) on October 21, 2021.
• The number of shares outstanding increased by 8.51% in one year.
• As of August 5, 2024, the company had 70,669,131 shares of common stock outstanding.

Inbound Investments

• Significant institutional investors hold shares, with FMR LLC, Lord Abbett & CO. LLC, and Wellington Management Group LLP being among the most heavily invested.
• The company reported a cash position of $209 million as of the end of Q2 2025.